Skip Navigation

JNCI Journal of the National Cancer Institute 1993 85(1):41-44; doi:10.1093/jnci/85.1.41
© 1993 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Leichman, C. G.
Right arrow Articles by Groshen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leichman, C. G.
Right arrow Articles by Groshen, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 85, No. 1, 41-44, January 6, 1993
© 1993 Oxford University Press

Prolonged Continuous Infusion of Fluorouracil With Weekly Bolus Leucovorin: A Phase II Study in Patients With Disseminated Colorectal Cancer

Cynthia Gail Leichman, Lawrence Leichman, C. Paul Spears, Peter J. Rosen, Susan Jeffers, Susan Groshen

University of Southern California Los Angeles, Calif.

Correspondence to: Cynthia G. Leichman, M.D., Division of Medical Oncology, Department of Medicine, University of Southern California School of Medicine, 1200 N. State St. #10-611, Los Angeles, CA 90033.

Background: Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%. In view of the short half-life of 5-FU and its cell cycle specificity, it may be that infusion rather than intravenous bolus injection would increase efficacy. Furthermore, the advent of safer indwelling intravenous catheters and pump technology, allowing home and ambulatory treatment, has made protracted infusion clinically feasible. To examine these questions, we conducted a phase I trial using protracted infusion of 5-FU by indwelling catheter and pump, with leucovorin given by bolus injection, and reported 40% partial response. Purpose: We have now initiated a phase II study of 5-FU given by prolonged continuous infusion with weekly bolus injections of leucovorin in previously untreated patients with measurable, disseminated colorectal cancer. Methods: Forty-one patients were treated. The regimen consisted of treatment for 4 weeks with 5-FU at a dose of 200 mg/m2 daily as a continuous infusion by indwelling intravenous catheter and pump, followed by a 2-week rest and then by monthly cycles of 3 weeks of treatment and 1-week rest until disease progression. Leucovorin was given as a bolus injection of 20 mg/m2 at the beginning of each week of treatment with 5-FU. Results: Nineteen (46%) of 41 patients had objective response: Three complete responses and 16 partial responses were seen. Overall, the median duration of response was 8 months. The median duration of survival was 16 months: 18 months for responders and 10 months for nonresponders. In general, toxic effects were mild and consisted primarily of stomatitis and palmar-plantar erythrodysesthesia (hand-foot syndrome). Neither grade 4 toxic effects nor treatment-related deaths were observed. The only serious side effects were catheter thrombosis (three patients) and catheter sepsis (one patient). Conclusion: We conclude that this safe regimen is one of the most effective for the treatment of disseminated colorectal cancer. Implications: The regimen should be tested prospectively against other regimens in use for this disease. It is currently included in a phase III study of the Southwest Oncology Group for this purpose. That study will assess quality of life as well as response rates and survival duration. [J Natl Cancer Inst 85:41–44, 1993]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
J. E Mortimer, M. K. Lauman, B. Tan, C. L Dempsey, A. C Shillington, and K. S Hutchins
Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine
Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 161 - 166.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero
Thymidylate Synthase Protein Expression in Primary Colorectal Cancer Compared with the Corresponding Distant Metastases and Relationship with the Clinical Response to 5-Fluorouracil
Clin. Cancer Res., December 1, 2000; 6(12): 4797 - 4802.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
D. Salonga, K. D. Danenberg, M. Johnson, R. Metzger, S. Groshen, D. D. Tsao-Wei, H.-J. Lenz, C. G. Leichman, L. Leichman, R. B. Diasio, et al.
Colorectal Tumors Responding to 5-Fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, and Thymidine Phosphorylase
Clin. Cancer Res., April 1, 2000; 6(4): 1322 - 1327.
[Abstract] [Full Text]

Home page
 JCOHome page
C. Aschele, D. Debernardis, S. Casazza, G. Antonelli, G. Tunesi, C. Baldo, R. Lionetto, F. Maley, and A. Sobrero
Immunohistochemical Quantitation of Thymidylate Synthase Expression in Colorectal Cancer Metastases Predicts for Clinical Outcome to Fluorouracil-Based Chemotherapy
J. Clin. Oncol., June 1, 1999; 17(6): 1760 - 1760.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.